Skip to content
Gowing L, Ali R, Dunlop A, Farrell M, Lintzeris N
National Drug Strategy
This document is intended to provide a broad policy context and a framework for medication-assisted treatment of opioid dependence.
It provides clinical guidelines on approaches involving the use of methadone, buprenorphine or naltrexone for the treatment of opioid dependence. It aims to provide guidance in the selection and management of patients seeking pharmacotherapies for opioid dependence, and to support the provision to patients of accurate information about methadone, buprenorphine and naltrexone.
This document updates and replaces four previously separate documents:
Abstract adapted from National Drug Strategy
These guidelines are primarily intended for generalist settings, such as general practice and hospital, clinic or community settings. Specialised alcohol and other drug treatment services may also find them helpful.
National Drug Strategy Team